introduction Diffuse large B-cell lymphoma (DLBCL) is one of the most common lymphoid neoplasms, characterized by heterogeneity in its clinical, immunophenotypic and genetic features [1, 2] . Recent studies have used gene expression profiling to identify the following three distinct subgroups of DLBCL: germinal center B-cell-like (GCB), activated B-cell-like and primary mediastinal (PM) DLBCL [2] [3] [4] . Several prognostic models on the basis of RNA or protein expression have been developed to predict survival in patients with DLBCL [5, 6] . However, a consensus on how to stratify patients with DLBCL has not been achieved. Many studies have also focused on immunohistochemistry as a method to identify risk groups; this technique avoids the requirement of fresh tissue and is easy to carry out in routine clinical practice.
Proliferation and progression of neoplastic cells are known to be closely related to abnormalities in various positive and negative cell-cycle regulators. The p27 kip1 protein (p27), a cyclindependent kinase (CDK) inhibitor, has an inhibitory effect on the G1-to-S phase transition in the cell cycle through its negative effects on cyclin E/CDK2 and cyclin A/CDK2 [7] . Downregulation of p27 has been shown to be mediated predominantly through the ubiquitin-dependent proteolytic pathway [8] . Ubiquitin ligase activity in the ubiquitination of p27 is provided by the Skp-Cullin-F-box complex, composed of S-phase kinaseassociated protein (Skp) 1, Cullin-1, ring-box 1 (Rbx-1) and the p27-specific F-box protein Skp2. Indeed, in human cancers and lymphomas, increased Skp2 expression and reciprocally decreased p27 expression have been demonstrated, indicating an oncogenic role for Skp2 in carcinogenesis and lymphomagenesis [9] [10] [11] . We previously demonstrated that Skp2 expression was a useful factor in determining outcome in patients with DLBCL [12] .
Addition of the anti-CD20 mAb rituximab to anthracyclinebased chemotherapy, such as the cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) regimen, has been shown to improve survival in patients with DLBCL [13] . The clinical applicability of a prognostic factor may depend on a specific therapy, and its usefulness should be reassessed when therapies change [14] . In this study, we used data from 671 patients with DLBCL treated with CHOP with or without rituximab from the Kyushu Lymphoma Study Group to retrospectively analyze whether Skp2 and p27 expression remains a valuable prognostic factor.
materials and methods patients
All the patients were treated with curative intent with a CHOP-like regimen (n = 425) or with cyclophosphamide, vincristine, doxorubicin and prednisolone plus rituximab (R-CHOP; n = 246) during the period 1995-2005, and clinical follow-ups were carried out up to 31 December 2006 at 22 hospitals in the Kyushu Lymphoma Study Group. Patients were enrolled on the basis of the following criteria: diagnosis of de novo DLBCL, availability of paraffin-embedded tissue obtained at diagnosis before the initiation of therapy and availability of follow-up and outcome data at the treating institutions. Cases of PM DLBCL or primary central nervous system lymphoma were not included in this study. Institutional review board approval was obtained from all the participating institutions. Clinical staging of DLBCL was carried out according to the Ann Arbor classification [15] by physical examination, evaluation of bone marrow specimens and computed tomography of the chest, abdomen and pelvis. The following clinical and laboratory data were available at the time of diagnosis: age, sex, performance status, stage, number of extranodal sites involved, serum lactate dehydrogenase level and the presence or absence of systemic (B) symptoms. On the basis of this information, International Prognostic Index (IPI) scores were determined for 671 patients, and the patients were categorized according to low and low-intermediate risk (low-risk group) and high-intermediate and high risk (high-risk group). None of the patients had a known history of human immunodeficiency virus infection or other forms of immunodeficiency.
Histological sections were used to diagnose DLBCL according to the World Health Organization classification of hematopoietic tumors [16] by pathologists at each institute. These sections were reviewed and diagnosis was confirmed at the Department of Pathology, Kurume University School of Medicine.
immunohistochemistry
Immunohistochemistry for the Skp2 protein was carried out using a polyclonal antibody against human Skp2 (H-435; Santa Cruz Biotechnology, Santa Cruz, CA) [17] . Staining of ‡40% of lymphoma cells was defined as a high expression of Skp2. Skp2 staining showed a robust and primarily nuclear signal, and the staining intensity did not vary among normal and neoplastic lymphoid cells. Staining and scoring for p27 (clone 57; Transduction Laboratories, Lexington, KY), CD10 (clone 56C6; Novocastra Laboratories, Newcastle upon Tyne, UK), Bcl-6 (clone P1F6; Novocastra Laboratories) and multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4, clone MUM1p; DAKO, Glostrup, Denmark) were carried out at the Department of Pathology, Kurume University School of Medicine [18] , by immunohistochemistry, and GCB and non-GCB DLBCL were classified according to the algorithm of Hans et al. [6] . Cut-off values for high expression were set at ‡20% of cells staining for p27 and ‡30% of cells staining for the CD10, Bcl-6 and MUM1 markers.
statistical analysis
Survival curves were estimated using the method of Kaplan-Meier and were compared using the log-rank test. Multivariate regression analysis according to the Cox proportional hazards regression model [19] was carried out with overall survival (OS) or progression-free survival (PFS). The Mann-Whitney U test or chi-square test was used to compare the clinical outcome between patient groups showing high Skp2 expression or low Skp2 expression and high p27 expression or low p27 expression. P <0.05 was considered significant.
results

patient characteristics
For the CHOP group, 425 patients aged 23-88 years (median 67.0 years) were investigated. The follow-up period ranged from 7 to 144 months (median 43.2 months). For the R-CHOP group, 246 patients aged 22-90 years (median 68.0 years) were studied. The follow-up period for the R-CHOP group ranged from 7 to 102 months (median 24.0 months). Patient and disease characteristics for both treatment cohorts, including the five clinical parameters comprising the IPI, are listed in Table 1 . In the R-CHOP group, OS and PFS were significantly better than in the CHOP group (P = 0.005 for OS, P < 0.001 for PFS). The 3-year OS rate was 63% for the CHOP group and 73% in the R-CHOP group, indicating a survival benefit from the addition of rituximab, consistent with several recent reports [13, 14] ( Figure 1A and B). High Skp2 expression was present in 166 of the 425 patients (39%) in the CHOP group and 91 of the 246 patients (37%) in the R-CHOP group. High Skp2 expression was found in both the GCB subtype (115 of 306: 38%) and the non-GCB subtype (142 of 365: 39%). High p27 expression was present in 192 of the 425 patients (45%) in the CHOP group and 154 of the 246 patients (63%) in the R-CHOP group. High p27 expression was found in both the GCB subtype (163 of 306: 53%) and the non-GCB subtype (183 of 365: 50%).
outcome analysis of the CHOP group on the basis of Skp2 expression
The relation between Skp2 expression and clinical outcome was examined ( Figure 2 ). The 3-year OS rate was 47% in the high Skp2 group and 73% in the low Skp2 group; the 3-year PFS rate was 37% and 59%, respectively. The OS and PFS times were significantly shorter in patients with high Skp2 expression (both P < 0.001) (Figure 2A and B). We also examined the prognostic impact of Skp2 expression using various cut-off values, and we found that in all cases, Skp2 expression remained a significant predictor of survival. These results indicated that higher Skp2 expression demonstrated worse OS ( Figure 2C ). In an attempt to exclude the contribution of lymphoma-unrelated deaths, the analysis was repeated in patients aged <74 years (327 of 425 patients, 77%); a similar correlation between Skp2 expression and OS was found (P < 0.001; data not shown). To examine whether the prognostic significance of Skp2 expression was independent of original article Annals of Oncology the IPI parameters, a multivariate Cox regression analysis was carried out and we found that the IPI parameters and the expression of Skp2 or p27 were independent predictors of OS (Table 2 ) and PFS (data not shown). We then specifically examined the indicating power of Skp2 expression in the prognosis for patients with low (n = 258) or high (n = 167) IPI scores. In the subgroup with high IPI scores, patients with high Skp2 expression exhibited significantly shorter OS (P < 0.001) ( Figure 2D ). An equivalent result was observed in patients with low IPI scores (P < 0.001 for OS) ( Figure 2E ).
outcome analysis in the R-CHOP group on the basis of Skp2 expression
The relationship between Skp2 expression and clinical outcome was studied in patients treated with R-CHOP. High Skp2 expression correlated with a lower 3-year OS rate compared with low Skp2 expression (50% versus 83%, respectively; P < 0.001). Similarly, the 3-year PFS rate was significantly lower in patients with a high Skp2 expression than in those with low Skp2 expression (45% versus 70%, respectively; P < 0.001).
The log-rank test revealed that Skp2 expression correlated significantly with both OS (P < 0.001) and PFS (P < 0.001; Figure 3A and B). We found that Skp2 expression at any cut-off value remained a significant predictor of survival, even in the R-CHOP group. These results indicated that higher Skp2 expression resulted in worse OS ( Figure 3C ). A multivariate Cox regression analysis revealed that Skp2 or p27 expression was an IPI-independent prognostic marker of OS (Table 2A) and PFS (data not shown) in the R-CHOP group. Analysis of OS in the subgroup with high IPI scores among patients treated with R-CHOP revealed that the high Skp2 group exhibited significantly worse OS (P < 0.001), compared with patients in the low Skp2 expression group ( Figure 3D) . A similar result was observed in patients with low IPI scores (P = 0.006 for OS; Figure 3E ).
survival impact of p27 expression
Patients with low p27 expression showed worse OS and PFS compared with those with high p27 expression in both treatment groups (P < 0.001) (Figure 4A-D) .
survival effects of both Skp2 and p27 expression pattern Survival curves for each subgroup divided by p27 and Skp2 expression were compared (OS in Figure 5A and C; PFS in Figure 5B and D). In the CHOP group (Figure 5A) , the subgroup of patients exhibiting high Skp2 and low p27 expression (n = 106) showed the lowest 3-year OS rate (39%), whereas the 3-year OS rate was highest (82%) in the low Skp2 and high p27 expression subgroup (n = 132) (P < 0.001). Similar results were obtained for PFS ( Figure 5B) (P < 0.001). In the R-CHOP group, the worst OS and PFS were found in patients with high Skp2 and low p27 expression ( Figure 5C and D) compared with other expression patterns of Skp2 and p27 (P < 0.001). Rituximab did not provide any outcome benefit in the high Skp2 and low p27, high Skp2 and low p27 expression groups (Figure 6A-C) . As shown in Table 2B and C, the results from hazard ratio also demonstrated that The addition of rituximab to the conventional CHOP regimen has been shown to improve outcome in patients with DLBCL in this cohort, as demonstrated in other papers [13, 20] . Consistent with our previous reports [12] , results of the present study clearly showed that Skp2 was a powerful predictor of outcome in patients with DLBCL and remained a significant factor in the determination of patient outcome, even when rituximab was incorporated. Recently, Udin et al. [21] also reported attractive results on the role of Skp2 in subset of DLBCL. In contrast, various other molecular factors, such as Bcl-2, MUM1/IRF4 and CD10, have been reported to be no longer accurate prognostic markers in immunohistochemical study when rituximab is introduced clinically [14, 22, 23] .
In the high Skp2 group, the 3-year OS was similar between patients treated with CHOP or R-CHOP ( Figure 6C ). In contrast, in the low Skp2 group, the 3-year OS was much better in patients treated with R-CHOP than in those treated with CHOP (Figures 2A and 3A) . A reciprocal effect was observed in OS for p27 expression ( Figure 4A and C) . This indicates that the use of rituximab does not provide a beneficial effect on outcome in patients with DLBCL with high Skp2 and low p27 expression ( Figure 6 ).
In addition to results from basic molecular research [10, 11] , this clinical study supports a pivotal role for Skp2 in lymphomagenesis. During the cell cycle G1-to-S phase transition, Skp2 degrades p27 [9] . These two proteins are therefore closely associated, and they exhibit a reciprocal expression pattern and prognostic relevance in several cancers [12, 24] . This is clearly shown in Figure 5 , where low Skp2/high p27 expression showed good survival compared with high Skp2/low p27 expression. However, 111 of 671 patients (17%) showed elevated expression of both p27 and Skp2, and 179 of 671 patients (27%) showed decreased expression of both p27 and Skp2. This implies that DLBCL cells might possess alternative regulatory systems for p27 that are independent of Skp2 ubiquitination. Recent studies have shown that cyclindependent kinase subunit (Cks) 1 is also required for the ubiquitination of p27 by bridging Skp2 and its substrate, p27, in vivo and in vitro [25] . Cks1 may also be closely related to p27 expression in some tumors [26] . In addition, systems other than Skp2/Cks1 may be involved in p27 proteolysis. Although p27 is predominantly degraded by Skp2 during the G1-S transition in the nucleus, p27 is also thought to be degraded by the Kip1 ubiquitination-promoting complex system in the cytoplasm during early G1 [27] . This nuclear export of p27 might be regulated by jun-activating domain-binding protein (Jab) 1 [28] . Cks1, Jab1 and other factors, together with Skp2, might play important regulatory roles in p27 degradation.
These additional regulatory proteins might also explain the ambiguous distribution of p27 and Skp2 in clinical samples.
Further comprehensive expression studies of these proteins are required to better understand the prognostic relevance of cell cycle-related proteins in patients with lymphoma. Skp2 has been reported to be an independent prognostic factor in various types of malignancies such as gastric cancers, oral squamous cell cancers and malignant lymphoma [12, 24] . In the present study, Skp2 and p27 protein expression was associated with prognosis in patients with DLBCL treated with CHOP or R-CHOP. In addition, the high Skp2 and low p27 expression group exhibited the most unfavorable prognosis, whereas the low Skp2 and high p27 expression group showed a better prognosis. Multivariate analysis revealed that Skp2 and p27 were independent prognostic factors in patients with DLBCL.
Several target proteins of Skp2-mediated proteolysis have been identified in addition to p27. Mice deficient in Skp2 show Figure 3 . Overall survival (OS) and progression-free survival (PFS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, vincristine, doxorubicin and prednisolone (R-CHOP). Patients were grouped according to their levels of S-phase kinase-associated protein 2 (Skp2) expression. Kaplan-Meier curves of OS (A) and PFS (B) in 246 patients with DLBCL show that high Skp2 expression correlated with a shorter OS (P < 0.001) and PFS (P < 0.001). Higher Skp2 expression (cut-off values: <40%, ‡40% to <80% and ‡80%) correlated with a shorter OS (C). Kaplan-Meier curves in 91 patients with high International Prognostic Index (IPI) scores showed that high Skp2 expression correlated with shorter OS (P < 0.001) (D). A similar result was observed in patients with low IPI scores (P = 0.006 for OS; E).
original article Annals of Oncology Figure 5 . Overall survival (OS) and progression-free survival (PFS) of patients with diffuse large B-cell lymphoma (DLBCL) on the basis of the pattern of Sphase kinase-associated protein 2 (Skp2) and p27 expression. Kaplan-Meier curves of OS and PFS in 425 patients treated with cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) (A and B) and 246 patients treated with cyclophosphamide, vincristine, doxorubicin and prednisolone plus rituximab (R-CHOP) (C and D) are shown according to the expression of Skp2 and p27. The group with high Skp2 and low p27 expression showed the most unfavorable outcome, and the group with low Skp2 and high p27 expression showed significantly better OS and PFS than other expression patterns of Skp2 and p27 (P < 0.001). an intracellular accumulation of p27 and cyclin E [11] . In addition, recent studies have revealed that Skp2 is a transcriptional coactivator of c-Myc, leading to transcriptional activation of target genes and subsequent enhanced cell proliferation and antiapoptosis; Skp2 is also responsible for proteasomal regulation of the Myc protein [29] . The synergistic interaction of c-Myc and Skp2 may enhance the aggressiveness of Skp2-overexpressing lymphoma cells. Even in the recent rituximab era, the expression pattern of Skp2 and p27 is an important prognostic factor in patients with DLBCL. Therapeutic strategies other than R-CHOP will be needed for patients with DLBCL who exhibit high Skp2 and low p27 expression at the time of diagnosis. Novel therapies that specifically target the cell cycle might be of benefit in subgroup of DLBCL.
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